C
Collplant Biotechnologies Ltd (CLGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$4.64
-0.02 (-0.43%)
Market Cap: $14.27M
Last updated: Nov 13, 2026 at 4:00 PM ET
Collplant Biotechnologies Ltd (CLGN) Valuation Multiples
Collplant Biotechnologies (CLGN) trades at 21.0x sales and 2.3x book value. Its forward P/E is 80.0x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 80.0x |
| Price to sales | 21.0x |
| Price to book | 2.3x |
|---|---|
| PEG | N/A |
| FCF yield | -174.8% |
As of Nov 13, 2026
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CLGN
What is CLGN's forward P/E ratio?
Collplant Biotechnologies has a forward P/E ratio of 80.0x.
Is CLGN stock overvalued?
GNG's valuation label for CLGN is Fairly valued.
What is CLGN's price to sales ratio?
Collplant Biotechnologies has a price to sales ratio of 21.0x.
CLGN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors